CareDx and Diaxonhit Announce Completion of Technology Transfer

 

BRISBANE, Calif. and PARIS, Jan. 12, 2016 — CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, and Diaxonhit (Alternext:ALEHT) (FR0004054427), a French leader in specialty in-vitro diagnostics for transplantation, infectious diseases and cancer, have announced the completion of the transfer of the CareDx proprietary AlloMap gene expression test into the Strasbourg University Hospital Central Immunology Laboratory (HUS) in France.  This rigorous, multi-step validation process has demonstrated that AlloMap test results released from the HUS laboratory are equivalent to AlloMap results generated by the CareDx main laboratory in the United States.  With the completion of this technology transfer, patient samples can now be tested at HUS.

Subscribe to get the latest news